Black Amanda, Gibson Todd M, Shiels Meredith S, Park Yikyung, Robien Kim, Albanes Demetrius, Weinstein Stephanie J, Freeman Laura E Beane, Andreotti Gabriella, Purdue Mark P, Fraumeni Joseph F, Hartge Patricia, Tucker Margaret A, Hoover Robert N, Cerhan James R, Zeleniuch-Jacquotte Anne, Curtis Rochelle E, Elena Joanne, Sampson Joshua N, Berrington de Gonzalez Amy, Morton Lindsay M
Division of Cancer Epidemiology and Genetics;
Department of Epidemiology and Biostatistics, George Washington University School of Public Health and Health Services, Washington, D.C.;
Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1598-608. doi: 10.1158/1055-9965.EPI-14-0191. Epub 2014 May 15.
With over 13 million cancer survivors in the United States today, second cancers are of rapidly growing importance. However, data on nontreatment risk factors for second cancers are sparse. We explored the feasibility of pooling data from cohort studies of cancer incidence to investigate second cancer etiology.
We combined data from five prospective studies including more than 800,000 individuals. We compared study designs and populations; evaluated availability of and ability to harmonize risk factor data; compared incidence and survival for common first primary malignancies and incidence of second primary malignancies; and estimated sample size requirements.
Overall, 96,513 incident, first primary malignancies were diagnosed during 1985 to 2009. Incidence rates and survival following the first primary varied among the cohorts, but most of the heterogeneity could be explained by characteristics of the study populations (age, sex, smoking, and screening rates). A total of 7,890 second primary cancers (excluding original primary site) were identified, yielding sufficient statistical power (≥80%) for detecting modest associations with risk of all second cancers among survivors of common first primary malignancies (e.g., colorectal cancer); however, there were insufficient events for studying survivors of rarer cancers or identifying risk factors for specific second cancers.
Pooling data from cohort studies to investigate nontreatment risk factors for second primary cancers seems feasible but there are important methodologic issues-some of which are barriers to specific research questions-that require special attention.
Increased understanding of nontreatment risk factors for second cancers will provide valuable prevention and surveillance information.
如今美国有超过1300万癌症幸存者,二次癌症的重要性正迅速增加。然而,关于二次癌症非治疗风险因素的数据却很稀少。我们探讨了合并癌症发病率队列研究数据以调查二次癌症病因的可行性。
我们合并了五项前瞻性研究的数据,涉及80多万人。我们比较了研究设计和人群;评估了风险因素数据的可用性和协调能力;比较了常见首次原发性恶性肿瘤的发病率和生存率以及二次原发性恶性肿瘤的发病率;并估计了所需样本量。
总体而言,198年至2009年期间共诊断出96513例首次原发性恶性肿瘤。各队列中首次原发性恶性肿瘤后的发病率和生存率各不相同,但大部分异质性可由研究人群的特征(年龄、性别、吸烟和筛查率)来解释。共识别出7890例二次原发性癌症(不包括原发部位),这为检测常见首次原发性恶性肿瘤(如结直肠癌)幸存者中与所有二次癌症风险的适度关联提供了足够的统计效力(≥80%);然而,研究罕见癌症幸存者或确定特定二次癌症的风险因素的事件数量不足。
合并队列研究数据以调查二次原发性癌症的非治疗风险因素似乎可行,但存在重要的方法学问题——其中一些是特定研究问题的障碍——需要特别关注。
对二次癌症非治疗风险因素的进一步了解将提供有价值的预防和监测信息。